AR007002A1 - Composicion de una materia conteniendo una sal de aril-heterociclo y una ciclodextrina o una sal de inclusion del mismo en una ciclodextrina - Google Patents

Composicion de una materia conteniendo una sal de aril-heterociclo y una ciclodextrina o una sal de inclusion del mismo en una ciclodextrina

Info

Publication number: AR007002A1
Authority: AR; Argentina
Prior art keywords: cyclodextrin; salt; ziprasidone; composition; hetero
Prior art date: 1996-05-07

Application number

ARP970101854A

Other languages

English (en)

Spanish (es)

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-07

Filing date

1997-05-05

Publication date

1999-10-13

1997-05-05 Application filed by Pfizer filed Critical Pfizer

1999-10-13 Publication of AR007002A1 publication Critical patent/AR007002A1/es

Links

229920000858 Cyclodextrin Polymers 0.000 title abstract 5
239000000203 mixture Substances 0.000 title abstract 4
150000003839 salts Chemical class 0.000 title abstract 4
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 4
239000000126 substance Substances 0.000 title 1
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 abstract 4
-1 ziprasidone Chemical class 0.000 abstract 3
229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 2
229960000607 ziprasidone Drugs 0.000 abstract 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 abstract 1
229950004221 besilate Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229950006327 napsilate Drugs 0.000 abstract 1
229940095064 tartrate Drugs 0.000 abstract 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nanotechnology (AREA)
Molecular Biology (AREA)
Medical Informatics (AREA)
Organic Chemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Crystallography & Structural Chemistry (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pyridine Compounds (AREA)
Seasonings (AREA)
Machine Translation (AREA)
Soil Conditioners And Soil-Stabilizing Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ARP970101854A 1996-05-07 1997-05-05 Composicion de una materia conteniendo una sal de aril-heterociclo y una ciclodextrina o una sal de inclusion del mismo en una ciclodextrina AR007002A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1920496P	1996-05-07	1996-05-07

Publications (1)

Publication Number	Publication Date
AR007002A1 true AR007002A1 (es)	1999-10-13

Family

ID=21791976

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ARP970101854A AR007002A1 (es)	1996-05-07	1997-05-05	Composicion de una materia conteniendo una sal de aril-heterociclo y una ciclodextrina o una sal de inclusion del mismo en una ciclodextrina
ARP040103099A AR045528A2 (es)	1996-05-07	2004-08-27	Sales de ziprasidona

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ARP040103099A AR045528A2 (es)	1996-05-07	2004-08-27	Sales de ziprasidona

Country Status (47)

Country	Link
US (2)	US6232304B1 (is)
EP (1)	EP0900088B1 (is)
JP (1)	JP3579060B2 (is)
KR (1)	KR20000010823A (is)
CN (1)	CN1216923A (is)
AP (1)	AP796A (is)
AR (2)	AR007002A1 (is)
AT (1)	ATE257714T1 (is)
AU (1)	AU713711B2 (is)
BG (3)	BG64474B1 (is)
BR (1)	BR9709213A (is)
CA (1)	CA2251912C (is)
CO (1)	CO4600677A1 (is)
CZ (1)	CZ297847B6 (is)
DE (1)	DE69727218T2 (is)
DK (1)	DK0900088T3 (is)
DZ (1)	DZ2220A1 (is)
EA (1)	EA001731B1 (is)
EG (1)	EG24135A (is)
ES (1)	ES2212809T3 (is)
GE (1)	GEP20074185B (is)
GT (1)	GT199700044A (is)
HN (1)	HN1997000039A (is)
HR (1)	HRP970237B1 (is)
HU (1)	HU222451B1 (is)
ID (1)	ID16866A (is)
IL (1)	IL126546A (is)
IS (1)	IS2524B (is)
MA (1)	MA24172A1 (is)
ME (1)	ME00880B (is)
MY (1)	MY121999A (is)
NO (1)	NO324373B1 (is)
NZ (1)	NZ332220A (is)
OA (1)	OA10907A (is)
PL (1)	PL189324B1 (is)
PT (1)	PT900088E (is)
RS (1)	RS49532B (is)
SA (1)	SA97180024B1 (is)
SI (1)	SI0900088T1 (is)
SK (1)	SK282032B6 (is)
TN (1)	TNSN97075A1 (is)
TR (1)	TR199802231T2 (is)
TW (1)	TW514529B (is)
UA (1)	UA57734C2 (is)
UY (1)	UY24544A1 (is)
WO (1)	WO1997041896A2 (is)
ZA (1)	ZA973874B (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0811386T3 (da) *	1996-05-07	2005-01-03	Pfizer	Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
UA57734C2 (uk) *	1996-05-07	2003-07-15	Пфайзер Інк.	Комплекси включення арилгетероциклічних солей
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en)	1998-04-29	2004-03-16	Osi Pharmaceuticals, Inc.	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) *	1999-05-10	2010-07-14	栄研化学株式会社	ホタルルシフェリンの安定化方法
US7087613B2 (en)	1999-11-11	2006-08-08	Osi Pharmaceuticals, Inc.	Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6884885B2 (en) *	2000-12-21	2005-04-26	Cerestar Holding B.V.	Production of cyclodextrin complexes
US7034013B2 (en) *	2001-03-20	2006-04-25	Cydex, Inc.	Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) *	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) *	2002-02-20	2004-03-11	Pfizer Inc.	Ziprasidone composition and synthetic controls
US6869939B2 (en) *	2002-05-04	2005-03-22	Cydex, Inc.	Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
DE60327225D1 (de) *	2002-08-20	2009-05-28	Bristol Myers Squibb Co	Aripiprazol-komplex-formulierung und verfahren
AU2003263413A1 (en) *	2002-09-17	2004-04-08	Warner-Lambert Company Llc	Heterocyclic substituted piperazines for the treatment of schizophrenia
JP2006514923A (ja) *	2002-10-25	2006-05-18	ファイザー・プロダクツ・インク	注射可能な新規なデポ製剤
JP2006505579A (ja) *	2002-10-25	2006-02-16	ファイザー・プロダクツ・インク	懸濁形態でのアリール複素環活性薬物の蓄積製剤
WO2004039410A2 (en) *	2002-10-31	2004-05-13	Pfizer Products Inc.	Liquid conjugates of solid pharmaceuticals
AU2003272011A1 (en) *	2002-10-31	2004-05-25	Pfizer Products Inc.	Solid and semi-solid polymeric ionic conjugates
EP1418492B1 (en)	2002-11-05	2017-09-20	LG Electronics, Inc.	Touch screen mounting assembly for LCD monitor
CN1255105C (zh) *	2002-12-17	2006-05-10	上海医药工业研究院	齐拉西酮及其盐的水溶性包合物及其制备方法
EP1546146A1 (en) *	2003-06-03	2005-06-29	Teva Pharmaceutical Industries Limited	POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
KR20090080143A (ko) *	2003-09-02	2009-07-23	화이자 프로덕츠 인크.	지프라시돈의 지속 방출형 투여 형태
CN1889943A (zh) *	2003-12-08	2007-01-03	美国亚利桑那大学董事会	协同抗癌组合物
EP1703898A2 (en) *	2003-12-31	2006-09-27	Alpharma, Inc.	Ziprasidone formulations
SI21703A (en) *	2004-01-14	2005-08-31	Lek Farmacevtska Druzba Dd	Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
WO2005107719A2 (en)	2004-05-06	2005-11-17	Sandoz Ag	Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) *	2004-05-26	2006-03-30	Pfizer Products Inc.	In vitro predictive method
US20070237828A1 (en) *	2004-06-11	2007-10-11	Dr. Reddy's Laboratories Limited	Ziprasidone Dosage Form
AU2005307797B2 (en) *	2004-11-16	2011-06-02	Alkermes Pharma Ireland Limited	Injectable nanoparticulate olanzapine formulations
CA2593497A1 (en) *	2005-02-11	2006-08-17	Judith Aronhime	Amorphous ziprasidone mesylate
US20080254114A1 (en) *	2005-03-03	2008-10-16	Elan Corporation Plc	Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
EP1858892A1 (en) *	2005-03-14	2007-11-28	Teva Pharmaceutical Industries Ltd	Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) *	2005-03-14	2007-11-28	Teva Pharmaceutical Industries Ltd.	Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) *	2005-08-17	2007-08-16	Bristol-Myers Squibb Company	FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en)	2006-10-02	2010-08-12	James Cloyd	Novel parenteral carbamazepine formulation
CN100391458C (zh) *	2006-02-07	2008-06-04	上海医药工业研究院	齐拉西酮或其盐包合物制备方法
KR20150081370A (ko)	2006-07-10	2015-07-13	파이온 유케이 리미티드	속효형 벤조디아제핀 염 및 이의 중합체 형태
CN101677568A (zh) *	2007-05-18	2010-03-24	赛多斯有限责任公司	齐拉西酮制剂
US8192721B2 (en) *	2007-12-13	2012-06-05	Verrow Pharmaceuticals, Inc.	Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) *	2008-05-09	2013-01-23	沈阳药科大学	桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
WO2011148253A2 (en)	2010-05-25	2011-12-01	Aurobindo Pharma Limited	Solid dosage forms of antipsychotics
EP2450039A1 (en)	2010-11-08	2012-05-09	PAION UK Ltd.	Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl)	2011-01-13	2012-07-31	Diagen@d@o@o	Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) *	2011-05-25	2014-12-17	上海医药工业研究院	卢拉西酮组合物
TW201332572A (zh)	2011-12-28	2013-08-16	Otsuka Pharma Co Ltd	具有經取代的β－環糊精之藥物製劑
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión
US20250049709A1 (en) *	2021-12-11	2025-02-13	Beloteca, Inc.	Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3459731A (en) *	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
IT1196033B (it)	1984-02-22	1988-11-10	Chiesi Farma Spa	Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es)	1987-03-02	1994-02-23	Pfizer	Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en)	1988-01-22	1989-11-28	Pfizer Inc.	Piperazinyl-heterocyclic compounds
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1255462B (it)	1992-07-28	1995-11-02	Grazia Maffione	Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en)	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it)	1993-01-29	1996-09-04	Paolo Chiesi	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en)	1993-05-24	1995-09-28	Europharmaceuticals Sa	Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it)	1994-04-22	1997-04-08	Chiesi Farma Spa	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr)	1994-06-16	1996-04-02	Europharmaceuticals Sa	Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
TW491847B (en)	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DK0811386T3 (da)	1996-05-07	2005-01-03	Pfizer	Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
IL126590A (en)	1996-05-07	2001-11-25	Pfizer	Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it
UA57734C2 (uk) *	1996-05-07	2003-07-15	Пфайзер Інк.	Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) *	1996-12-25	1998-07-28	Janssen Pharmaceut Nv	アシル化シクロデキストリン含有製薬組成物

1997
- 1997-01-04 UA UA98105560A patent/UA57734C2/uk unknown
- 1997-03-25 TW TW086103749A patent/TW514529B/zh not_active IP Right Cessation
- 1997-04-01 DE DE1997627218 patent/DE69727218T2/de not_active Expired - Lifetime
- 1997-04-01 PL PL97329928A patent/PL189324B1/pl unknown
- 1997-04-01 HU HU9902799A patent/HU222451B1/hu active IP Right Grant
- 1997-04-01 CZ CZ0346198A patent/CZ297847B6/cs not_active IP Right Cessation
- 1997-04-01 PT PT97907246T patent/PT900088E/pt unknown
- 1997-04-01 SK SK1504-98A patent/SK282032B6/sk not_active IP Right Cessation
- 1997-04-01 WO PCT/IB1997/000321 patent/WO1997041896A2/en not_active Ceased
- 1997-04-01 TR TR1998/02231T patent/TR199802231T2/xx unknown
- 1997-04-01 KR KR1019980708959A patent/KR20000010823A/ko not_active Ceased
- 1997-04-01 CA CA002251912A patent/CA2251912C/en not_active Expired - Lifetime
- 1997-04-01 NZ NZ332220A patent/NZ332220A/xx not_active IP Right Cessation
- 1997-04-01 AT AT97907246T patent/ATE257714T1/de active
- 1997-04-01 BR BR9709213A patent/BR9709213A/pt not_active Application Discontinuation
- 1997-04-01 ES ES97907246T patent/ES2212809T3/es not_active Expired - Lifetime
- 1997-04-01 DK DK97907246T patent/DK0900088T3/da active
- 1997-04-01 JP JP53966997A patent/JP3579060B2/ja not_active Expired - Lifetime
- 1997-04-01 EA EA199800910A patent/EA001731B1/ru not_active IP Right Cessation
- 1997-04-01 EP EP97907246A patent/EP0900088B1/en not_active Expired - Lifetime
- 1997-04-01 SI SI9730623T patent/SI0900088T1/xx unknown
- 1997-04-01 ME MEP-1997-172A patent/ME00880B/me unknown
- 1997-04-01 AU AU19372/97A patent/AU713711B2/en not_active Expired
- 1997-04-01 IL IL12654697A patent/IL126546A/xx not_active IP Right Cessation
- 1997-04-01 US US09/147,239 patent/US6232304B1/en not_active Expired - Lifetime
- 1997-04-01 CN CN97194242A patent/CN1216923A/zh active Pending
- 1997-04-02 HN HN1997000039A patent/HN1997000039A/es unknown
- 1997-04-10 GT GT199700044A patent/GT199700044A/es unknown
- 1997-04-28 CO CO97022511A patent/CO4600677A1/es unknown
- 1997-04-30 AP APAP/P/1997/000977A patent/AP796A/en active
- 1997-05-04 EG EG37897A patent/EG24135A/xx active
- 1997-05-05 ID IDP971488A patent/ID16866A/id unknown
- 1997-05-05 AR ARP970101854A patent/AR007002A1/es active IP Right Grant
- 1997-05-06 DZ DZ970067A patent/DZ2220A1/fr active
- 1997-05-06 MA MA24596A patent/MA24172A1/fr unknown
- 1997-05-06 RS YU17297A patent/RS49532B/sr unknown
- 1997-05-06 TN TNTNSN97075A patent/TNSN97075A1/fr unknown
- 1997-05-06 MY MYPI97001984A patent/MY121999A/en unknown
- 1997-05-06 UY UY24544A patent/UY24544A1/es not_active IP Right Cessation
- 1997-05-06 ZA ZA973874A patent/ZA973874B/xx unknown
- 1997-05-07 HR HR970237A patent/HRP970237B1/xx not_active IP Right Cessation
- 1997-05-12 SA SA97180024A patent/SA97180024B1/ar unknown
1998
- 1998-10-27 IS IS4880A patent/IS2524B/is unknown
- 1998-10-30 OA OA9800204A patent/OA10907A/en unknown
- 1998-11-03 BG BG102894A patent/BG64474B1/bg unknown
- 1998-11-03 BG BG108606A patent/BG64475B2/bg unknown
- 1998-11-06 NO NO19985192A patent/NO324373B1/no not_active IP Right Cessation
2001
- 2001-05-07 US US09/850,658 patent/US6399777B2/en not_active Expired - Lifetime
2004
- 2004-02-25 BG BG108606A patent/BG64475B1/bg unknown
- 2004-08-27 AR ARP040103099A patent/AR045528A2/es not_active Application Discontinuation
2006
- 2006-12-13 GE GEAP20069762A patent/GEP20074185B/en unknown

Also Published As

Publication number	Publication date
EA199800910A1 (ru)	1999-04-29
BG64475B2 (bg)	2005-04-30
AU1937297A (en)	1997-11-26
CZ346198A3 (cs)	1999-09-15
HUP9902799A3 (en)	2000-12-28
AP9700977A0 (en)	1997-07-31
PL189324B1 (pl)	2005-07-29
US6232304B1 (en)	2001-05-15
EP0900088A2 (en)	1999-03-10
EP0900088B1 (en)	2004-01-14
IS4880A (is)	1998-10-27
YU17297A (sh)	1999-12-27
KR20000010823A (ko)	2000-02-25
UY24544A1 (es)	2000-09-29
IS2524B (is)	2009-07-15
NZ332220A (en)	2000-03-27
HRP970237B1 (en)	2002-04-30
PT900088E (pt)	2004-04-30
JP3579060B2 (ja)	2004-10-20
ATE257714T1 (de)	2004-01-15
ES2212809T3 (es)	2004-08-01
TNSN97075A1 (fr)	2005-03-15
WO1997041896A2 (en)	1997-11-13
IL126546A (en)	2001-01-28
AU713711B2 (en)	1999-12-09
SK150498A3 (en)	2000-01-18
DE69727218T2 (de)	2004-11-18
BG64474B1 (bg)	2005-04-30
GT199700044A (es)	1998-10-02
BG102894A (en)	1999-09-30
WO1997041896A3 (en)	1998-01-08
AR045528A2 (es)	2005-11-02
AP796A (en)	1999-12-24
IL126546A0 (en)	1999-08-17
JPH11509866A (ja)	1999-08-31
HN1997000039A (es)	1997-06-26
NO324373B1 (no)	2007-10-01
SA97180024B1 (ar)	2005-12-24
GEP20074185B (en)	2007-08-10
CA2251912C (en)	2003-06-03
MY121999A (en)	2006-03-31
TR199802231T2 (xx)	1999-02-22
CA2251912A1 (en)	1997-11-13
BG64475B1 (bg)	2005-04-30
ZA973874B (en)	1998-11-06
PL329928A1 (en)	1999-04-26
DZ2220A1 (fr)	2002-12-03
BR9709213A (pt)	1999-08-10
NO985192D0 (no)	1998-11-06
MA24172A1 (fr)	1997-12-31
HU222451B1 (hu)	2003-07-28
OA10907A (en)	2001-10-26
ME00880B (me)	2006-12-15
ID16866A (id)	1997-11-20
RS49532B (sr)	2006-12-15
US6399777B2 (en)	2002-06-04
CN1216923A (zh)	1999-05-19
EG24135A (en)	2008-08-06
US20010031756A1 (en)	2001-10-18
CZ297847B6 (cs)	2007-04-11
DK0900088T3 (da)	2004-04-19
UA57734C2 (uk)	2003-07-15
HRP970237A2 (en)	1998-12-31
HUP9902799A2 (hu)	1999-12-28
TW514529B (en)	2002-12-21
DE69727218D1 (de)	2004-02-19
SK282032B6 (sk)	2001-10-08
CO4600677A1 (es)	1998-05-08
EA001731B1 (ru)	2001-08-27
NO985192L (no)	1998-11-06
SI0900088T1 (en)	2004-04-30

Legal Events

Date	Code	Title	Description
2005-11-29	FG	Grant, registration

Publication	Publication Date	Title
CO4600677A1 (es)	1998-05-08	Complejos de inclusion de sales de aril-heterociclicos
DK175288B1 (da)	2004-08-09	Farmaceutiske midler indeholdende lægemidler, der er ustabile eller sparsomt oplöselige i vand, og fremgangsmåder til deres fremstilling
HUP9901037A2 (hu)	1999-07-28	Piperazinszármazékok, előállításuk és alkalmazásuk, ezeket a vegyületeket tartalmazó gyógyászati készítmények
DE60011827D1 (de)	2004-08-05	Kosmetische Zusammensetzungen enthaltend ein Hydroxyalkylether-Aniontensid und ein kationisches Polymer, und ihre Verwendungen
KR950704269A (ko)	1995-11-17	당뇨병 치료제
PE20011122A1 (es)	2001-11-06	DERIVADOS DE PURINA-2-ILCARBOXAMIDA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA
ES8506007A1 (es)	1985-06-01	Un procedimiento para la preparacion de 1h-imidazoles y 1h-1, 2, 4-triazoles
UY25857A1 (es)	2001-07-31	4-alquenil (y alquinil) oxindoles los cuales inhiben las quinasas dependientes de ciclina (cdks)
NO20015419L (no)	2001-12-20	Propionsyrederivater som hemmer binding av integriner til deres reseptorer
KR960022553A (ko)	1996-07-18	신규한 에리스로마이신 유도체, 그의 제조 방법 및 의약으로서의 용도
KR900004316A (ko)	1990-04-12	요오드화물과 회합된 모노히드록시인돌에 의한 케라틴 섬유염색방법 및 사용한 조성물
BR9805875A (pt)	2000-05-02	Composições farmacêuticas de droloxifeno.
BR0013262A (pt)	2002-04-16	Formulações de agentes branqueadores fluorescentes
DK0399633T3 (da)	1995-05-15	Leukotrien B4-derivater, fremgangsmåde til fremstilling heraf samt deres anvendelse som lægemiddel
ATE474550T1 (de)	2010-08-15	Verwendung von beta-cyclodextrin mit tensiden als perlmuttschimmer-mittel
ES2124546T3 (es)	1999-02-01	Agentes de blanqueo acuosos.
ECSP972098A (es)	1998-04-07	Complejos de inclusion de sales de aril meterociclicos
RU2000114807A (ru)	2002-05-10	Пиперазин-циклодекстриновый комплекс
JP3429324B2 (ja)	2003-07-22	ケラチン繊維用染色剤
ES2153925T3 (es)	2001-03-16	Agente acuoso para el fregado a mano de la vajilla.
MY155914A (en)	2015-12-15	Indolylpiperidine derivatives as antihistaminic and antiallergic agents
JPS644620B2 (is)	1989-01-26
JPS6340555A (ja)	1988-02-20	便座用テイツシユペ−パ−
ZA200110383B (en)	2002-12-19	Fungicidal combinations of active substances.
EE05178B1 (et)	2009-06-15	1,3-dioksolaanid, nende saamine ja kasutamine khavastaste ravimite valmistamiseks ning neid sisaldavad farmatseutilised kompositsioonid